[March 25, 2014] |
 |
Transgene Schedules Conference Call to Discuss 2013 Financial Results
STRASBOURG, France --(Business Wire)--
Regulatory News:
Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) today announced that the
Company will hold a conference call to discuss financial results for
fiscal year 2013 and to provide a business update. The results will be
published on March 26, 2014 in advance of the call.
The conference call, which will be conducted in English, will be held on Wednesday,
March 26, 2014 at 1 PM EDT/6 PM CET. A replay of the call will be
available on the Transgene website (www.transgene.fr)
following the live event.
Webcast link:
http://www.media-server.com/m/p/otmy5xpe
Participant telephone numbers:
France: +33 (0)1 70 99 42 76 United Kingdom: +44 (0)20 3427 1901 US:
+1 212 444 0895
Confirmation Code: 5911562
Participants will need to provide the above code when dialing into the
call.
About Transgene
Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group,
is a publicly traded French biopharmaceutical company focused on
discovering, developing and manufacturing targeted immunotherapies for
the treatment of oncology and infectious diseases. Transgene's programs
utilize well-tolerated viruses with the goal of indirectly or directly
killing infected or cancerous cells. The Company's four clinical-stage
programs are: TG4010 for non-small cell lung cancer; Pexa-Vec for liver
cancer; TG4001 for oropharyngeal cancer (under a collaboration agreement
with the EORTC) and TG4040 for chronic Hepatitis C. Transgene has
concluded corporate strategic agreements for the development of two of
its immunotherapy products: an exclusive option agreement with Novartis
for the development and commercialization of TG4010 and an in-licensing
agreement with U.S.-based Jennerex, Inc. for the development and
commercialization of Pexa-Vec in certain territories. The Company also
has several programs in research and pre-clinical development that are
based on its core viral vector technology. Transgene is based in
Strasbourg, France, and has additional operations in Lyon, as well as
satellite offices in China and the U.S. Additional information about
Transgene is available at www.transgene.fr.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140325006193/en/
[ Back To TMCnet.com's Homepage ]
|